Tag Archives: GARY

PIONEER: rivaroxaban and antiplatelets reduce bleeding in AF post-PCI A combination of two different strategies of the non-vitamin K oral antagonist, rivaroxaban, plus either mono or dual antiplatelet therapy (DAPT), significantly reduced the risk of clinically significant bleeding compared to standard triple therapy in patients with atrial fibrillation after percutaneous coronary intervention (PCI). PIONEER AF PCI (Two Treatment Strategies of Rivaroxaban and a Dose-adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention) was an open-label, randomised, controll

TAVI for asymptomatic and intermediate risk patients Indications for transcatheter aortic valve implantation (TAVI) are a critical aspect of determining the future of the therapy and this became a recurrent theme of the meeting. Current guidelines do not support the use of TAVI for those with asymptomatic aortic stenosis, as argued by Dr Bernard Prendergast (John Radcliffe Hospital, Oxford). There are some scenarios, however, where TAVI for asymptomatic aortic stenosis is appropriate, such as an immobile patient in whom symptoms have not appeared, or a frail patient with rapid progression of the condition. To date, there have been three prope

WOEST: aspirin not required for stent patients on oral anticoagulants  A strategy of using clopidogrel as a single antiplatelet drug for patients receiving a drug-eluting stent who are also taking an oral anticoagulant appears safe and can reduce bleeding, the results of the WOEST study suggest. How to treat patients on anticoagulation when they receive a stent is fraught with difficulty as giving the normal dual antiplatelet therapy with aspirin and clopidogrel means they will be taking three anti-clotting agents which could increase bleeding complications to a dangerous level. But no randomised clinical trials have ever investigated whethe